189 related articles for article (PubMed ID: 32622946)
1. Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.
Kanemasa T; Matsuzaki T; Koike K; Hasegawa M; Suzuki T
Life Sci; 2020 Sep; 257():118048. PubMed ID: 32622946
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Profile of Naldemedine, a Peripherally Acting
Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
[TBL] [Abstract][Full Text] [Related]
3. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting.
Sato J; Tanaka R; Ishikawa H; Suzuki T; Shino M
Support Care Cancer; 2020 Mar; 28(3):1083-1088. PubMed ID: 31183560
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.
Kanemasa T; Koike K; Arai T; Ono H; Horita N; Chiba H; Nakamura A; Morioka Y; Kihara T; Hasegawa M
Neurogastroenterol Motil; 2019 May; 31(5):e13563. PubMed ID: 30821019
[TBL] [Abstract][Full Text] [Related]
5. Naldemedine: Peripherally Acting Opioid Receptor Antagonist for Treating Opioid-induced Adverse Effects.
Inagaki M; Kanemasa T; Yokota T
Curr Top Med Chem; 2020; 20(31):2830-2842. PubMed ID: 32648846
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes.
Suzuki T; Sawada T; Kawai K; Ishihara Y
Life Sci; 2018 Dec; 215():246-252. PubMed ID: 30036489
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X; Wang D; Qu X; Dong N; Teng S
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
[TBL] [Abstract][Full Text] [Related]
8. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
9. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist.
Watari R; Matsuda A; Ohnishi S; Hasegawa H
Drug Metab Pharmacokinet; 2019 Apr; 34(2):126-133. PubMed ID: 30770183
[TBL] [Abstract][Full Text] [Related]
10. Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects.
Inagaki M; Kume M; Tamura Y; Hara S; Goto Y; Haga N; Hasegawa T; Nakamura T; Koike K; Oonishi S; Kanemasa T; Kai H
Bioorg Med Chem Lett; 2019 Jan; 29(1):73-77. PubMed ID: 30446313
[TBL] [Abstract][Full Text] [Related]
11. Effect of a selective GABA(B) receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects.
Suzuki T; Nurrochmad A; Ozaki M; Khotib J; Nakamura A; Imai S; Shibasaki M; Yajima Y; Narita M
Neuropharmacology; 2005 Dec; 49(8):1121-31. PubMed ID: 16095635
[TBL] [Abstract][Full Text] [Related]
12. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
[TBL] [Abstract][Full Text] [Related]
13. Naldemedine: A Review in Opioid-Induced Constipation.
Blair HA
Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
[TBL] [Abstract][Full Text] [Related]
14. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
Wild J; Yamada T; Arjona Ferreira JC; Hale M
Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
[TBL] [Abstract][Full Text] [Related]
15. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
Fukumura K; Yamada T; Yokota T; Kawasaki A
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):162-174. PubMed ID: 30977959
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M; Ahmad D; Hewlett A
J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
[TBL] [Abstract][Full Text] [Related]
17. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
Pergolizzi JV; Christo PJ; LeQuang JA; Magnusson P
Drug Des Devel Ther; 2020; 14():1009-1025. PubMed ID: 32210534
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Webster LR; Yamada T; Arjona Ferreira JC
Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
[TBL] [Abstract][Full Text] [Related]
19. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.
Streicher JM; Bilsky EJ
J Pharm Pract; 2018 Dec; 31(6):658-669. PubMed ID: 28946783
[TBL] [Abstract][Full Text] [Related]
20. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]